← Back to Pipeline Dashboard Open Source Medicine Foundation

RSV MAT

Discontinued / Inactive

Developer: GlaxoSmithKline  |  Target Disease: RSV

Program Status: Inactive / Discontinued

Reason: Registry status: TERMINATED, WITHDRAWN

Stage at discontinuation: phase_3

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View RSV Vaccine Guide →
Development Phase Discontinued / Inactive Primary Status
Platform Technology Biological (unspecified platform) Biologic Architecture
Target Indication RSV Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture
Biological (unspecified platform)
Lead Developer
GlaxoSmithKline
Next Expected Milestone
Primary completion (most advanced trial): 2023-11-06 (registry estimate)
Analyst & Development Notes
Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT05229068 →
Additional Sources & Literature

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT05229068 Discontinued / Inactive

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Partici

Status: Active / Ongoing • Expected Readout: 2023-11-06
NCT04605159 Discontinued / Inactive

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women

Status: Active / Ongoing • Expected Readout: 2023-06-14
NCT04980391 Discontinued / Inactive

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 t

Status: Active / Ongoing • Expected Readout: 2023-05-30

Milestone Overview

  • Stage Verification
    Discontinued / Inactive confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2023-11-06 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.